Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 7/20 | 0.38 |
| ▸ | ARG1 | P05089 | 5/20 | 0.38 |
| ▸ | ARG2 | P78540 | 4/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.37 |
| ▸ | FAP | Q12884 | 4/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2735532 | 0.90 | CPB2 (0.40) | XIAPDPP4ARG1ARG2EPHX1 | |
| SCHEMBL2735524 | 0.89 | KMT2A (0.48) | MEN1LMNAKMT2AXIAPDPP4 | |
| SCHEMBL14655011 | 0.89 | KMT2A (0.48) | MEN1LMNAKMT2AXIAPDPP4 | |
| SCHEMBL5967831 | 0.85 | SMYD3 (0.46) | MEN1LMNAKMT2AXIAPDPP4 | |
| SCHEMBL28661580 | 0.85 | SMYD3 (0.46) | MEN1LMNAKMT2AXIAPDPP4 | |
| SCHEMBL15054947 | 0.85 | SMYD3 (0.46) | MEN1LMNAKMT2AXIAPDPP4 | |
| SCHEMBL10459274 | 0.82 | DPP4 (0.39) | XIAPDPP4ARG1ARG2DPP7 | |
| SCHEMBL10458504 | 0.82 | XIAP (0.37) | MEN1LMNAKMT2AXIAPDPP4 | |
| SCHEMBL10459272 | 0.82 | XIAP (0.37) | MEN1LMNAKMT2AXIAPDPP4 | |
| SCHEMBL10457308 | 0.82 | DPP4 (0.39) | XIAPDPP4ARG1ARG2DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-02-23 | — | — | US | disclosed |
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-02-23 | — | — | US | disclosed |
| US-8088823-B2 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-01-03 | — | — | US | disclosed |
| US-8088823-B2 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-01-03 | — | — | US | disclosed |
| EP-1501495-B1 | USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI | NABRIVA THERAPEUTICS AG (AT) | 2010-09-08 | — | — | EP | disclosed |
| US-7790749-B2 | Use of pleuromutilins for the treatment of disorders caused by Helicobacter pylori | NABRIVA THERAPEUTICS AG (AT) | 2010-09-07 | — | — | US | disclosed |
| US-7790749-B2 | Use of pleuromutilins for the treatment of disorders caused by Helicobacter pylori | NABRIVA THERAPEUTICS AG (AT) | 2010-09-07 | — | — | US | disclosed |
| EP-1875903-B1 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | NABRIVA THERAPEUTICS AG (AT) | 2010-07-28 | — | — | EP | disclosed |
| EP-1875903-A1 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | Nabriva Therapeutics Forschungs GmbH (AT) | 2008-01-09 | — | — | EP | disclosed |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2007-11-22 | — | — | US | disclosed |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | PLEC, TTR, TREH | MEN1 559/4885LMNA 1879/4885KMT2A 4575/4885 |
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | PLEC, TTR, TREH | MEN1 559/4885LMNA 1879/4885KMT2A 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.